Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $11.59 and traded as low as $11.07. Cidara Therapeutics shares last traded at $11.22, with a volume of 16,728 shares traded.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the stock. StockNews.com raised shares of Cidara Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, September 13th. Cantor Fitzgerald reissued an "overweight" rating on shares of Cidara Therapeutics in a report on Wednesday, August 14th. HC Wainwright reissued a "buy" rating and issued a $24.00 target price on shares of Cidara Therapeutics in a report on Tuesday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $25.00 target price on shares of Cidara Therapeutics in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Cidara Therapeutics has a consensus rating of "Buy" and a consensus price target of $29.67.
View Our Latest Analysis on CDTX
Cidara Therapeutics Stock Up 1.4 %
The firm's 50 day simple moving average is $11.57 and its 200 day simple moving average is $12.28. The company has a market cap of $51.92 million, a price-to-earnings ratio of -1.48 and a beta of 1.03.
Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($2.05) EPS for the quarter, beating the consensus estimate of ($3.94) by $1.89. Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 109.89%. The company had revenue of $0.30 million for the quarter. Analysts anticipate that Cidara Therapeutics, Inc. will post -12.06 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Cidara Therapeutics stock. Tocqueville Asset Management L.P. lifted its stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 71.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 163,000 shares of the biotechnology company's stock after acquiring an additional 68,000 shares during the quarter. Tocqueville Asset Management L.P. owned about 3.57% of Cidara Therapeutics worth $150,000 at the end of the most recent reporting period. 35.82% of the stock is currently owned by institutional investors.
About Cidara Therapeutics
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
See Also
Before you consider Cidara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.
While Cidara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
